Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

References

• Linch D C, Winfield D, Goldstone A H, Moir D, Hancock B, McMillan A, et al. Dose intensification in autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelle H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Van Putten W LJ, Hagenbeek A, Schouten H C, Sonneyeld P, van Imhoff O W, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051
   PubMed Web of Science ®Google Scholar
• Stockerl-Goldstein K E, Horning S J, Negrin R S, Chao N J, Hu W W, Long O D, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplants 1996; 2: 76–85
   PubMedGoogle Scholar
• Vose J M, Anderson J R, Kessinger A, Bierman P J, Loccla P, Reed E C, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851
   PubMed Web of Science ®Google Scholar
• Rapoport A T, Row J M, Kouides P A, Puerst R A, Abboud C N, Liesveld J L, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, O'Donnell M R, Dagis A, Snyder D S, Parker P, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk, intermediate and high-grade lymphoma: International Index High and High-Intermediate Risk Group. Blood 1997; 90: 3844–3852
   PubMed Web of Science ®Google Scholar
• Bierman P J, Armitage J O. Role of autotransplantation in Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7: 591–611
   PubMed Web of Science ®Google Scholar
• Goldstone A H, McMillan A K. The place of high dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 1993; 4: 21–27
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A K, Linch D C, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Wang E H, Chen Y A, Corringham S, Bashey A, Holman P, Ball E D, et al. High-dose CEB vs. BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004; 34: 581–587
   PubMed Web of Science ®Google Scholar
• Arranz R, Tomas J F, Gil-Fernández J J, Martinez-Chamorro C, Granados E, Alegre A, et al. Autologous stem cell transplantation for poor prognostic Hodgkin's disease: comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21: 779–786
   PubMed Web of Science ®Google Scholar
• Carella A M, Congiu A M, Gaozza E, Mazza P, Ricci P, Visani G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Study Group report. J Clin Oncol 1986; 6: 1411–1416
   Web of Science ®Google Scholar
• Reece D E, Connors J M, Spinelli J J, Barnett M J, Fairey R N, Klingeman H G, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplants 1997; 3: 98–106
   PubMedGoogle Scholar
• Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta J J, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's Disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Horning S, Chao N J, Negrin R S, Hoppe R T, Long G D, Hu W W, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Patti C, Majolino I, Scime R, Indovina A, Vasta S, Liberti G, et al. High-dose cyclophosphamide, etoposide and carmustine (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993; 51: 18–24
   PubMed Web of Science ®Google Scholar
• Strauss D J, Gaynor J J, Myers J, Merke D P, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non cross-resistant chemo-therapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E. Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH 84 regimen. Blood 1989; 74: 558–564
   PubMed Web of Science ®Google Scholar
• Villela L, Sureda A, Canals C, Sanz M A, Jr, Martino R, Valcárcel D, et al. Low transplant-related mortality in older patients with hematological malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300–305
   PubMed Web of Science ®Google Scholar
• McDonald G B, Sharma P, Matthews D E, Shulman H M, Thomas E D. Veno-occlusive disease of the liver after marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–122
   PubMed Web of Science ®Google Scholar
• Jones R J, Lee K S, Beschorner W E, Vogel V G, Grochow L B, Braine H G, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783
   PubMed Web of Science ®Google Scholar
• Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997; 20: 1063–1067
   PubMed Web of Science ®Google Scholar
• Bearman S I, Appelbaum F R, Back A, et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288–1294
   PubMed Web of Science ®Google Scholar
• Bianco J A, Appelbaum F R, Nemuanitis J, Almgren J, Andrews F, Kettner P, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205–1211
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Gray R J. A class of K-sample test for comparing the cumulative incidence of competing risk. Ann Stat 1988; 16: 1141–1154
   Web of Science ®Google Scholar
• Pepe M S, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure time data. Stat Med 1993; 12: 737–751
   PubMed Web of Science ®Google Scholar
• Reece D E, Barnett M J, Connors J M, Fairey R N, Fay J W, Greer J P, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871–1879
   PubMed Web of Science ®Google Scholar
• Reece D E, Connors J M, Spinelli J J, Barnett M J, Fairey R N, Klingemann H G, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide, cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Reece D E, Barnett M J, Shepherd J D, Hogge D E, Klasa R J, Nantel S H, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16 – 213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451–456
   PubMed Web of Science ®Google Scholar
• Ayash L J, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699–1706
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Bacigalupo A, Alberti A, van Lint M T, Uderzo C, Marmont A M, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68–72
   PubMed Web of Science ®Google Scholar
• Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J, et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529–534
   PubMed Web of Science ®Google Scholar
• McDonald G B, Hinds M S, Fisher L D, Schoch H G, Wolford J L, Banajl M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267
   PubMed Web of Science ®Google Scholar
• Carreras E, Bertz H, Arcese W, Verhant J P, Tomas J F, Hagglund H, et al. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 1998; 92: 3599–3604
   PubMed Web of Science ®Google Scholar
• Wadhwa P D, Fu P, Koc O N, Cooper B W, Fox R M, Creger R J, et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplants 2005; 11: 13–22
   PubMed Web of Science ®Google Scholar
• Todd N W, Peters W P, Ost A H, Roggli V L, Piantadosi C A, et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1264–1270
   PubMed Web of Science ®Google Scholar
• Cherniack R M, Abrams J, Kalica J. Pulmonary disease associated with breast cancer therapy. Am J Resp Crit Care Med 1994; 150: 1169–1173
   PubMed Web of Science ®Google Scholar
• Stuart M J, Chao N S, Horning S J, Wong R M, Negrin R S, Johnston L J, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen foll-owed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplants 2001; 7: 552–560
   PubMed Web of Science ®Google Scholar
• Ager S, Mahendra P, Richards E M, Bass G, Baglin T P, Marcus R E, et al. High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996; 17: 335–340
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin J H, Churchill W H, Come S E, Smith B R, Bubley G J, et al. Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648–656
   PubMed Web of Science ®Google Scholar
• Cao T M, Negrin R S, Stockerl-Goldstein K E, Johnston L J, Shizuru J A, Taylor T L, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplants 2000; 6: 387–394
   PubMed Web of Science ®Google Scholar
• Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279–285
   PubMed Web of Science ®Google Scholar